Please login to the form below

Not currently logged in
Email:
Password:

epigenetics

This page shows the latest epigenetics news and features for those working in and with pharma, biotech and healthcare.

Researchers reverse Alzheimer’s memory loss in mice

Researchers reverse Alzheimer’s memory loss in mice

The Buffalo researchers believe their work in the developing science of epigenetics will yield answers in the elusive search for new Alzheimer's therapies. ... The researchers found that the loss of glutamate receptors resulted from an epigenetic process

Latest news

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    The expansion of Alzheimer’s R&D is underpinned by evidence that the disease has a range of drivers, including Abeta, inflammation and epigenetics, that evolve as it progresses. ... And a host of other academic and industry teams are looking at

  • Deal Watch November 2016 Deal Watch November 2016

    licence, collaboration. 207.5. Proterosos biostructures/ Merck &Co (MSD). second collaboration to develop small molecules against an additional epigenetic target for various cancers.

  • Deal Watch January 2016 Deal Watch January 2016

    Tensha has developed an epigenetic technology that disrupts bromodomain and extra terminal domain (BET) proteins in order to develop potential treatments for cancer. ... 535. Rodin/ Biogen. Collaboration. Multi-year neuronal epigenetics research

  • Deal Watch October 2015 Deal Watch October 2015

    Proteros' epigenetics technology and structure guided discovery platform for oncology targets (discovery).

  • Pharma deals in August 2015 Pharma deals in August 2015

    This situation occurred when Genentech/Roche elected not to go further with their option to acquire the epigenetics drug discovery company, Constellation Pharmaceuticals.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Professor Thomas Cech joins Storm Therapeutics Professor Thomas Cech joins Storm Therapeutics

    mature into a world leading therapeutics company targeting RNA epigenetic modulation.”.

  • Storm Therapeutics bolsters its team Storm Therapeutics bolsters its team

    As a clinician-scientist at the University of Melbourne, Professor Dawson has experience in epigenetics having spent several years researching epigenetic regulation of leukaemia stem cells. ... Keith Blundy, chief executive officer of Storm Therapeutics,

  • Storm Therapeutics strengthens its board Storm Therapeutics strengthens its board

    RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies. ... We look forward to Paul’s input on development and positioning of Storm’s emerging RNA epigenetics platform and programmes.”.

  • Rubius Therapeutics strengthens senior team Rubius Therapeutics strengthens senior team

    He most recently served as the senior vice president and head of the cancer epigenetics department at GlaxoSmithKline, where he was responsible for overall strategy, as well as identification and validation ... of new epigenetic targets and advancing

  • Paul Stockdale joins Oxford BioDynamics as CFO Paul Stockdale joins Oxford BioDynamics as CFO

    A spin-out from Oxford University, Oxford BioDynamics focuses on the discovery and development of epigenetic biomarkers based on regulatory genome architecture.

More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics